Autologous mesenchymal stem cells of bone marrow in combined treatment of pharmacoresistant epilepsy
Abstract
MATERIALS AND METHODS. The indicators of 15 patients with pharmacoresistant forms of epilepsy were evaluated, who, along with the constant intake of antiepileptic drugs, were administered AMSC BM and a comparison group consisting of 20 patients. The effectiveness of treatment after AMSC BM transplantation was evaluated in 10 patients after 6, 12 or more months from the beginning of the treatment according to the clinical condition and EEG data.
SUMMARY. These data confirm the safety and prospects of using AMSC BM for the treatment of patients with pharmacoresistant epilepsy. It was found that the course therapy AMSC BM can be achieved significant improvement in patients with primary and secondary generalized seizures, complex partial psychomotor paroxysms
THE AIM OF THE STUDY was to develop a method for the treatment of epilepsy using autologous mesenchymal stem cells of bone marrow (AMSC BM), assess their safety and effectiveness.
About the Authors
F. Hlebokazov
Republican Scientific and Practical Center for Mental Health
Belarus
Belarus
Minsk
T. Dakukina
Republican Scientific and Practical Center for Mental Health
Belarus
Belarus
Minsk
M. Potapnev
Republican Scientific and Practical Center for Transfusion and Medical Biotechnology
Belarus
Belarus
Minsk
S. Kosmacheva
Republican Scientific and Practical Center for Transfusion and Medical Biotechnology
Belarus
Belarus
Minsk
I. Shamruk
Republican Scientific and Practical Center for Mental Health
Belarus
Belarus
Minsk
S. Orlova
The Republican Research and Practical Center for Epidemiology and Microbiology
Belarus
Belarus
Minsk
E. Slobina
Republican Scientific and Practical Center for Mental Health
Belarus
Belarus
Minsk
A. Martynenka
Republican Scientific and Practical Center for Mental Health
Belarus
Belarus
Minsk
References
1. Вермель А. Е. Стволовые клетки: общая характеристика и перспективы применения в клинической практике. Клиническая медицина № 1, 2004; 5–11.
2. Докукина Т.В., Мисюк Н. Н. Визуальная и компьютерная ЭЭГ в клинической практике, Минск, 2018. — 203 с.
3. Квачева З.Б., Вотяков В. И., Титов Л. П. и др. Стволовые клетки. Перспективы их применения в медицине. Медицинский журнал № 4, 2005; 4–6.
4. Киссин, М. Я. Клиническая эпилептология. — М.: ГЭОТАР — Медиа, 2009. — 256с.
5. Климович В. Б. Иммуномодулирующая активность мезенхимальных стромальных (стволовых) клеток //Медицинская иммунология 2014, Т. 16, № 2, стр. 107–126.
6. Одинак М.М., Бисага Г. Н., А. В. Новицкий. Аутологичная трансплантация мультипотентных мезенхимальных стволовых клеток при боковом амиотрофическом склерозе и рассеянном склерозе.// Вестн. Рос. Воен.-мед. акад. — 2009. — № 3. — С. 38–42.
7. Hlebokazov F., Dakukina T., et al., Treatment of refractory epilepsy patients with autologous mesenchymal stem cells reduces seizure frequency: An open label study: Advances in Medical Sciences, Volume 62, Issue 2, September 2017, P. 273–279.
8. Le Blanc, K. et al. HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890–896
9. Shetty AK, Upadhya D. GABA-ergic cell therapy for epilepsy: Advances, limitations and challenges. Neurosci Biobehav Rev. 2016; 62:35–47.
10. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663–676.
Review
For citations:
Hlebokazov F., Dakukina T., Potapnev M., Kosmacheva S., Shamruk I., Orlova S., Slobina E., Martynenka A. Autologous mesenchymal stem cells of bone marrow in combined treatment of pharmacoresistant epilepsy. Russian Neurosurgical Journal named after Professor A. L. Polenov. 2019;11(4):47-52. (In Russ.)
Views:
7
Email this article 